Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

3 Stocks Near 52-Week Highs Worth Selling: Regions Financial Corporation (RF), Barclays PLC (ADR) (BCS), Cree, Inc. (CREE)

Page 1 of 2

Not even the enacting of $85 billion in budget cuts has been enough to keep more than 50% of companies in the Motley Fool CAPS Screener from creeping within 10% of a new 52-week high. For skeptics like me, that’s an opportunity to see whether companies have earned their current valuations.

Keep in mind that some companies deserve their current valuations. Southern regional bank Regions Financial Corporation (NYSE:RF) is a great example. In its most recent quarter, Regions reported a $265 million profit, reversing a huge $548 million year-ago loss, and noted that its net interest margin expanded two basis points to 3.1% as it shed and paid off undesirable commercial real estate assets. As the economy continues to improve, Regions Financial Corporation (NYSE:RF) loan quality should improve as well, sending this company markedly higher.

Regions Financial Corporation (NYSE:RF)Still, other companies might deserve a kick in the pants. Here’s a look at three companies that could be worth selling.

This is speculating, not investing
The past week has been like 1999 all over again for mortgage insurers like Radian Group Inc (NYSE:RDN) and MGIC Investment Corp. (NYSE:MTG) . Both companies were upgraded on Tuesday by Barclays PLC (ADR) (NYSE:BCS) analyst Mark DeVries, who sees sector earnings returning to normal by 2015 as bad legacy loans are slowly wiped off the books. He also set price targets of $14 on Radian and $8 on MGIC, which was practically a double from the $4.18 it closed at prior to the upgrade. Today, I’m going to rake MGIC over the coals once again!

DeVries’ call has definitely brought out the message-board day traders, but little substance exists behind his analysis on MGIC, in my opinion. To begin with, I’ll point to the company’s abysmal and worsening operating performance, which includes 10 straight quarterly losses and a risk-to-capital ratio of 44.7:1 that’s only expected to worsen and is approaching double of what U.S. regulators would consider safe on the top-end of their estimates. Even with its situation improving, 13.9% of all loans are still delinquent — certainly not a manageable figure.

There’s also the fact that MGIC’s plan to get back into compliance involves crushing shareholders who’ve ridden this rally higher by issuing 135 million shares and $350 million in convertible debt. Furthermore, underwriters have the option to purchase an additional $50 million in convertible debt. Prior to this offering, MGIC had only 202 million shares outstanding. Following this offering, and hypothetically including the potential conversion of all debt to shares, MGIC’s outstanding shares count could more than double to 408 million shares. This type of dilution should quickly crush MGIC’s share price!

Sky-high valuation
There’s a fine line to be walked in the software-as-a-service sector between sky-high valuations and incredible growth rates. Unfortunately, I don’t feel that E2open Inc (NASDAQ:EOPN) makes the cut.

E2open, which provides on-demand supply chain management software for enterprises, delivered solid growth in its third-quarter results released in early January. Revenue rose 31% to $19.5 million and the company increased its booking forecast for 2013 to 30%-35%. However, there are plenty of negatives counteracting this rapid growth.

To begin with, E2open is still burning through cash and losing money. Its 2013 projections call for a free cash outflow of $3.1 million to $4.2 million and a loss of $0.06-$0.08 per share. With sales growth expected to slow to just 22% according to the Street’s estimates in 2014, is it worth paying 433 times forward earnings? I’d certainly say, “No!” What’s more, it isn’t as if E2open is sitting on a gigantic pile of cash, either. Yes, it boasts $32.4 million in net cash, but, that doesn’t make up for the fact that it’s valued at seven time sales and 26 times book value. It’ll be years before E2open’s costs are brought under control, which makes further upside seem very unlikely.

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!